Phase 2 study of BKM120 in patients with advanced esophagus cancer
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
Price : $35 *
At a glance
- Drugs Buparlisib (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 06 Jun 2017 Primary endpoint (Disease control rate) has been met, according to the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 16 Mar 2017 Status changed from active, no longer recruiting to discontinued.